During the European Association for the Study of Diabetes (EASD) annual meeting in Copenhagen in 1990, the hypothesis was put forward that administration of the gut hormone GLP-1 may be a novel glucose-reducing therapy for both type 1 and type 2 diabetes (9). This evidence concerns the gene GLP1R and diabetes mellitus.